Sunday, March 31, 2024 3:31:39 PM
MRD is 10.9% at risk at five years for DCVax-l
Long term survival is where the impact is expected to be highest with cancer vaccine therapy.
You’ll also notice it appears significant residual disease (where I logically assume most mesenchymal are) will surpass minimum residual disease by year six.
This would not be the case with SOC therapy. It would be the opposite, and by a much wider margin.
(And of course SOC SRD OS would be less than half that by that time, essentially zero)
Recent NWBO News
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
